StockData
Pelthos Therapeutics Inc. logo

Pelthos Therapeutics Inc. (PTHS) stock

PTHSNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$6.84−0.31 (-4.34%)

Close on Nov 17, 2026Market cap $26.19MP/E –Yield –

Pelthos Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

Pelthos Therapeutics's gross margin for the twelve months ending Jun 30, 2026 was 78.6%. For fiscal 2025 it was 76.3%.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202576.3%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202676.9%–
Q1 FY2026Mar 31, 202684.7%–
Q4 FY2025Dec 31, 202582.2%–
Q3 FY2025Sep 30, 202568.7%–

More Pelthos Therapeutics figures

See a number that looks wrong?